Craig Boyce

Craig Boyce is a prominent figure in the biotech investment sector, currently serving as the Managing Partner at the ALS Investment Fund since 2017. His work focuses on supporting and financing companies that are developing disease-modifying therapeutics specifically for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. Under his leadership, the fund has made significant investments, including backing Amylyx Pharmaceuticals, which developed the third FDA-approved drug for ALS in September 2022.12

Professional Background

Craig Boyce has over 25 years of experience in strategic consulting and private equity investing. He spent 18 years at Bain Capital, where he rose to Managing Director, working across various industries and regions, including Boston and Hong Kong. His expertise extends to serving on the boards of several companies, such as MYOB and Retail Zoo, and he has been involved with various nonprofit organizations related to ALS and community service.134

Education

Boyce holds a Bachelor of Science in Chemical Engineering with High Honors from Princeton University, a Master of Science in Chemical Engineering from the Massachusetts Institute of Technology, and an MBA in General Management from Harvard Business School.1

Community Involvement

In addition to his professional endeavors, Craig is actively engaged in his local community in Orleans, Massachusetts. He participates as a Scout leader and coaches youth sports, reflecting his commitment to fostering growth and development in younger generations.1

Investment Philosophy

The ALS Investment Fund aims to build a diversified portfolio of companies focused on neurodegenerative diseases. The fund seeks out biotech firms with innovative approaches and proven scientific foundations, emphasizing investments that can lead to significant advancements in treatment options for ALS and related conditions.24

Craig Boyce's extensive background in both investment and community service positions him as a key player in the fight against ALS through innovative therapeutic solutions.